HDAX Therapeutics is pioneering best-in-class therapeutics for neurological and cardiovascular diseases. Leveraging its unique molecular recognition platform technology, HDAX engineered a novel 2-site binding mechanism targeting HDAC6, a key protein implicated in microtubule dysfunction. Its approach addresses critical drug-design obstacles, including weak-binding, off-target toxicities, and suboptimal pharmacokinetic profiles, unlocking the potential to translate into better treatments for patients. HDAX’s initial focus is peripheral neuropathies (CIPN and CMT), with additional applications in heart failure and neurodegeneration.

HDAX Therapeutics logo



Event details

Date: June 3 - 6, 2024

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


42 in total